Look, But Don't Use: European Medicines Agency Clinical Trial Data Terms Are Pointless

The European Medicines Agency (EMA) receives comprehensive clinical study data from drug manufacturers and that data form the basis for the decision on the approval of new drugs.  In 2013, EMA issued a draft policy to make clinical study data available to researchers and decision-makers, with extensive data transparency, a move which Science 2.0 applauded. But the latest policy clarification is a puzzle, because it accomplishes almost nothing of any value to the broad community.  Only reading allowed read more

Read the whole article on

More from